Zhao Cong, Zhang Zhi-Dan, Zhang Xiao-Juan, Li Xu, Zhu Ran, Ma Xiao-Chun
Department of ICU, The First Hospital of China Medical University, Shenyang 110001, China.
Zhonghua Nei Ke Za Zhi. 2009 Jul;48(7):566-9.
To investigate the therapeutic effects of low-dose heparin on sepsis.
Seventy-nine sepsis patients were randomly divided into two groups: heparin treatment group (n = 37) and routine treatment group (n = 42). The 7-day and 28-day mortality, the days in ICU and the length of stay, the changes of oxygenation index, the days of mechanical ventilation and the rates of disseminated intravascular coagulation (DIC), acute renal failure (ARF), acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) were observed. The levels of APTT, PT and platelet (PLT) count were determined before and after treatment in two groups.
The rates of DIC, ARF and MODS in heparin group decreased significantly after therapy: rate of DIC, 15.4% vs 38.7% (P = 0.03); rate of ARF, 25.0% vs 51.9% (P = 0.04); rate of MODS, 26.3% vs 50.0% (P = 0.04). In heparin group, the 28-day mortality was statistically reduced (15.4% vs 32.4%, P = 0.03). The differences between heparin group and routine group were not statistically significant in the 7-day mortality (7.7% vs 12.9%, P = 0.08), the days in ICU (Z = 0.281, P = 0.779, rank sum test), the length of stay (Z = 0.562, P = 0.574, rank sum test), the oxygenation index (P = 0.82), the days of mechanical ventilation [(126.07 +/- 166.21) h vs (179.27 +/- 221.7) h, P = 0.28] and the rate of ARDS (44.0% vs 46.2%, P = 0.88). The differences in APTT, PT and PLT were not significant between the two groups.
Low-dose heparin can decrease the mortality rate of sepsis and improve the prognosis of patients. It is a safe promising therapy in sepsis patients without severe side effects.
探讨小剂量肝素对脓毒症的治疗效果。
79例脓毒症患者随机分为两组:肝素治疗组(n = 37)和常规治疗组(n = 42)。观察两组患者7天和28天死亡率、入住重症监护病房(ICU)天数和住院时间、氧合指数变化、机械通气天数以及弥散性血管内凝血(DIC)、急性肾衰竭(ARF)、急性呼吸窘迫综合征(ARDS)和多器官功能障碍综合征(MODS)的发生率。测定两组患者治疗前后活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)和血小板(PLT)计数水平。
肝素组治疗后DIC、ARF和MODS的发生率显著降低:DIC发生率,15.4% 对38.7%(P = 0.03);ARF发生率,25.0% 对51.9%(P = 0.04);MODS发生率,26.3% 对50.0%(P = 0.04)。肝素组28天死亡率有统计学意义的降低(15.4% 对32.4%,P = 0.03)。肝素组与常规组在7天死亡率(7.7% 对12.9%,P = 0.08)、入住ICU天数(Z = 0.281,P = 0.779,秩和检验)、住院时间(Z = 0.562,P = 0.574,秩和检验)、氧合指数(P = 0.82)、机械通气天数[(126.07 ± 166.21)小时对(179.27 ± 221.7)小时,P = 0.28]以及ARDS发生率(44.0% 对46.2%,P = 0.88)方面差异无统计学意义。两组间APTT、PT和PLT差异无显著意义。
小剂量肝素可降低脓毒症患者死亡率,改善患者预后。对脓毒症患者是一种安全且有前景的治疗方法,无严重副作用。